No increased cardiovascular risk detected for new diabetes medication

(Brigham and Women's Hospital) An international, multidisciplinary team including investigators from Brigham and Women's Hospital has found that lixisenatide, a member of a class of glucose-lowering drugs frequently prescribed in Europe to patients with diabetes, did not increase risk of cardiovascular events including heart failure. These results -- the first to be reported on the cardiovascular safety of a glucagon-like peptide 1 receptor agonist -- were presented today at the American Diabete...